Abstract
At the end of 2005, six European countries had implemented public immunisation campaigns with serogroup C conjugate vaccines to date and all had experienced substantial declines in the incidence of serogroup C disease. A quadrivalent ACWY meningococcal vaccine is in use in the USA, but serogroup A is extremely rare in Europe and serogroups Y and W-135 are infrequent causes of disease. This paper outlines recommendations about the use of conjugate vaccines in Europe, based on the experience with MCC vaccines so far.
| Translated title of the contribution | Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines |
|---|---|
| Original language | English |
| Pages (from-to) | 101 - 107 |
| Number of pages | 7 |
| Journal | FEMS Microbiology Reviews |
| Volume | 31 (1) |
| DOIs | |
| Publication status | Published - Jan 2007 |